X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with Lupin Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs LUPIN LTD - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE LUPIN LTD CADILA HEALTHCARE/
LUPIN LTD
 
P/E (TTM) x 36.5 17.5 208.6% View Chart
P/BV x 9.4 4.1 230.6% View Chart
Dividend Yield % 0.7 0.8 86.2%  

Financials

 CADILA HEALTHCARE   LUPIN LTD
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-16
LUPIN LTD
Mar-16
CADILA HEALTHCARE/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs4542,127 21.4%   
Low Rs3051,294 23.5%   
Sales per share (Unadj.) Rs96.1304.1 31.6%  
Earnings per share (Unadj.) Rs14.950.4 29.5%  
Cash flow per share (Unadj.) Rs17.860.7 29.4%  
Dividends per share (Unadj.) Rs3.207.50 42.7%  
Dividend yield (eoy) %0.80.4 192.3%  
Book value per share (Unadj.) Rs52.3243.8 21.4%  
Shares outstanding (eoy) m1,023.74450.58 227.2%   
Bonus/Rights/Conversions FV5:1--  
Price / Sales ratio x3.95.6 70.2%   
Avg P/E ratio x25.533.9 75.2%  
P/CF ratio (eoy) x21.328.2 75.5%  
Price / Book Value ratio x7.37.0 103.4%  
Dividend payout %21.514.9 144.6%   
Avg Mkt Cap Rs m388,458770,740 50.4%   
No. of employees `00015.416.4 94.4%   
Total wages/salary Rs m13,31721,077 63.2%   
Avg. sales/employee Rs Th6,371.18,379.6 76.0%   
Avg. wages/employee Rs Th862.41,289.0 66.9%   
Avg. net profit/employee Rs Th986.11,388.7 71.0%   
INCOME DATA
Net Sales Rs m98,376137,016 71.8%  
Other income Rs m9411,877 50.1%   
Total revenues Rs m99,317138,893 71.5%   
Gross profit Rs m23,82937,535 63.5%  
Depreciation Rs m3,0224,635 65.2%   
Interest Rs m486446 108.9%   
Profit before tax Rs m21,26234,330 61.9%   
Minority Interest Rs m-300-88 342.5%   
Prior Period Items Rs m50-   
Extraordinary Inc (Exp) Rs m-250-   
Tax Rs m5,71611,536 49.6%   
Profit after tax Rs m15,22622,707 67.1%  
Gross profit margin %24.227.4 88.4%  
Effective tax rate %26.933.6 80.0%   
Net profit margin %15.516.6 93.4%  
BALANCE SHEET DATA
Current assets Rs m44,37697,790 45.4%   
Current liabilities Rs m34,07153,872 63.2%   
Net working cap to sales %10.532.1 32.7%  
Current ratio x1.31.8 71.8%  
Inventory Days Days5485 63.6%  
Debtors Days Days62121 51.4%  
Net fixed assets Rs m47,89686,379 55.4%   
Share capital Rs m1,024901 113.6%   
"Free" reserves Rs m48,746105,735 46.1%   
Net worth Rs m53,519109,844 48.7%   
Long term debt Rs m8,96453,739 16.7%   
Total assets Rs m100,163224,378 44.6%  
Interest coverage x44.777.9 57.4%   
Debt to equity ratio x0.20.5 34.2%  
Sales to assets ratio x1.00.6 160.8%   
Return on assets %15.710.3 152.0%  
Return on equity %28.420.7 137.6%  
Return on capital %34.321.2 161.7%  
Exports to sales %45.349.1 92.2%   
Imports to sales %5.97.4 79.7%   
Exports (fob) Rs m44,53767,244 66.2%   
Imports (cif) Rs m5,83810,199 57.2%   
Fx inflow Rs m44,88171,405 62.9%   
Fx outflow Rs m9,06917,807 50.9%   
Net fx Rs m35,81253,598 66.8%   
CASH FLOW
From Operations Rs m19,938-3,690 -540.4%  
From Investments Rs m-9,039-69,434 13.0%  
From Financial Activity Rs m-9,52758,126 -16.4%  
Net Cashflow Rs m1,372-14,998 -9.1%  

Share Holding

Indian Promoters % 74.8 46.6 160.5%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 8.3 11.3 73.5%  
FIIs % 5.9 31.9 18.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 10.1 108.9%  
Shareholders   44,069 98,259 44.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   PANACEA BIOTECH  AJANTA PHARMA  ALEMBIC LTD  DR. DATSONS LABS  ELDER PHARMA  

Compare CADILA HEALTHCARE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Flat Finish to the Week; Cadila Healthcare Rallies 7%(Closing)

Indian share markets finished marginally higher for the week in a thin trade amid buying in pharma stocks, software stocks and capital good stocks.

Related Views on News

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Lupin: Key Products Drive US growth (Quarterly Results Update - Detailed)

Sep 12, 2016

Lupin has announced its 1QFY17results. Net sales have grown by 40% YoY and net profits have surged by 55.1% YoY. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

Dear PM Modi, India is Already Land of Self-Employed, and It Ain't Working(Vivek Kaul's Diary)

Aug 21, 2017

Most Indians who cannot find jobs, look at becoming self-employed.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

Think Twice Before You Keep Money In A Savings Bank Account(Outside View)

Aug 22, 2017

Post demonetisation, a cut in bank savings deposits rates was in the offing.

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Aug 24, 2017 03:36 PM

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 5-YR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS